- Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatoc…
Number of the records: 1  

Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular crcinoma conversion therapy: a prospecitve, single-arm phase II trial

  1. LIU, Dongming. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular crcinoma conversion therapy: a prospecitve, single-arm phase II trial. In Neoplasma. ISSN 0028-2685. Bratislava : AEPress, 2023, 2023, vol. 70, no. 6, s. 811-818.
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.